The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women’s Hospital, Boston, MA) about the use of vupanorsen and the safety and efficacy of the TRANSLATE-TIMI 7 trial.
Questions:
- What is vupanorsen and what is the rationale for its use as a lipid-lowering agent? (00:19)
- What are the aims, design, and eligibility criteria of the TRANSLATE-TIMI 7 clinical trial? (01:34)
- What were the efficacy and safety findings of the study? (03:02)
- What will be the next step in the clinical development of vupanorsen in this indication? (04:25)
- What are the other potential indications of vupanorsen? (06:15)
Disclosures: Brian Bergmark discloses grant/research support from Pfizer, AstraZeneca and Ionis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
